Dalargin (DALE) has originally been proposed as an antiulcer agent with cytoprotective properties; but it has been tested for other activities with promising results. Dalargin shows antioxidant; antiischemic; and wound-healing properties.
CAT No: HB00104
CAS No: 81733-79-1
Synonyms/Alias: Dalargin;81733-79-1;Enkephalin-leu, ala(2)-arg(6)-;2-Ala-6-Arg-Leu-enkephalin;DALARGINE;(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid;UNII-V13505565P;DALARGIN [WHO-DD];BRN 4287455;Tyr-D-Ala-Gly-Phe-Leu-Arg;2-D-Alanine-1-6-beta-neoendorphin (human);DTXSID50231302;1-6-(D-ALA2)-DYNORPHIN;Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine;tageflar;V13505565P;1-6-beta-Neoendorphin (human), 2-D-alanine-;N(sup 2)-(N-(N-(N-(L-Tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)-L-leucyl)-L-arginine;1-6-.BETA.-NEOENDORPHIN (HUMAN), 2-D-ALANINE-;L-ARGININE, L-TYROSYL-D-ALANYLGLYCYL-L-PHENYLALANYL-L-LEUCYL-;L-Arginine, N(sup 2)-(N-(N-(N-(L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)-L-leucyl)-;Tyr-Ala-Gly-Phe-Leu-Arg;Leu-enkephalin, Ala(2)-Arg(6)-;leucine-enkephalin, Ala(2)-Arg(6)-;enkephalin, Ala(2)-Leu(5)-Arg(6)-;enkephalin-Leu, alanyl(2)-arginine(6)-;(D-Ala2)-Leu-Enkephalin-Arg acetate salt;tyrosyl-alanyl-glycyl-phenylalanyl--leucyl-arginine;DTXCID10153793;EX-A5715;H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH;HY-P4053;FA108952;CS-0635584;Q27291394;(2S,5S,8S,14R,17S)-17-amino-8-benzyl-2-(3-guanidinopropyl)-18-(4-hydroxyphenyl)-5-isobutyl-14-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaoctadecan-1-oic acid;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C35H51N9O8 |
M.W/Mr. | 725.8 |
Sequence | One Letter Code:YAGFLR Three Letter Code:H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH |
Appearance | Lyophilized powder |
Biological Activity | dalargin shows antioxidant, antiischemic, and wound-healing properties. |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C35H51N9O8/c1-20(2)16-27(32(49)43-26(34(51)52)10-7-15-39-35(37)38)44-33(50)28(18-22-8-5-4-6-9-22)42-29(46)19-40-30(47)21(3)41-31(48)25(36)17-23-11-13-24(45)14-12-23/h4-6,8-9,11-14,20-21,25-28,45H,7,10,15-19,36H2,1-3H3,(H,40,47)(H,41,48)(H,42,46)(H,43,49)(H,44,50)(H,51,52)(H4,37,38,39)/t21-,25+,26+,27+,28+/m1/s1 |
InChI Key | GDPHPXYFLPDZGH-XBTMSFKCSA-N |
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.